Peringatan Keamanan

Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.

Moxifloxacin

DB00218

small molecule approved investigational

Deskripsi

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Struktur Molekul 2D

Berat 401.4314
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 11.5-15.6 hours (single dose, oral)
Volume Distribusi * 1.7 to 2.7 L/kg
Klirens (Clearance) * 12 +/- 2 L/hr

Absorpsi

Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.

Metabolisme

Approximately 52% or oral or intravenous dose is metabolized via glucuronide and sulphate conjugation. The cytochrome P450 system is not involved in metabolism. The sulphate conjugate accounts for 38% of the dose, and the glucuronide conjugate accounts for 14% of the dose.

Rute Eliminasi

Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces).

Interaksi Makanan

2 Data
  • 1. Drink plenty of fluids.
  • 2. Take with or without food.

Interaksi Obat

926 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Moxifloxacin.
Didanosine Didanosine can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Probenecid Probenecid may decrease the excretion rate of Moxifloxacin which could result in a higher serum level.
Quinapril Quinapril can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium acetate Calcium acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevelamer Sevelamer can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Dextran Iron Dextran can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Calcium can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lanthanum carbonate Lanthanum carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric carboxymaltose Ferric carboxymaltose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron sucrose Iron sucrose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric pyrophosphate Ferric pyrophosphate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric sulfate Ferric sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric cation Ferric cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetraferric tricitrate decahydrate Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lanthanum III cation Lanthanum III cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxyhydroxide Ferric oxyhydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate Sucralfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Moxifloxacin.
Nitrofurantoin The therapeutic efficacy of Moxifloxacin can be decreased when used in combination with Nitrofurantoin.
Agomelatine The serum concentration of Agomelatine can be increased when it is combined with Moxifloxacin.
Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Moxifloxacin.
Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Moxifloxacin.
Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Moxifloxacin.
Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Moxifloxacin.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Moxifloxacin.
Insulin human The therapeutic efficacy of Insulin human can be increased when used in combination with Moxifloxacin.
Insulin lispro The therapeutic efficacy of Insulin lispro can be increased when used in combination with Moxifloxacin.
Insulin pork The therapeutic efficacy of Insulin pork can be increased when used in combination with Moxifloxacin.
Troglitazone The therapeutic efficacy of Troglitazone can be increased when used in combination with Moxifloxacin.
Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Moxifloxacin.
Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Moxifloxacin.
Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Moxifloxacin.
Metformin The therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.
Sulfadiazine The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Moxifloxacin.
Rosiglitazone The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Moxifloxacin.
Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Moxifloxacin.
Miglitol The therapeutic efficacy of Miglitol can be increased when used in combination with Moxifloxacin.
Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Moxifloxacin.
Nateglinide The therapeutic efficacy of Nateglinide can be increased when used in combination with Moxifloxacin.
Pentamidine The therapeutic efficacy of Pentamidine can be increased when used in combination with Moxifloxacin.
Tolazamide The therapeutic efficacy of Tolazamide can be increased when used in combination with Moxifloxacin.
Repaglinide The therapeutic efficacy of Repaglinide can be increased when used in combination with Moxifloxacin.
Phenformin The therapeutic efficacy of Phenformin can be increased when used in combination with Moxifloxacin.
Sulfamethoxazole The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Moxifloxacin.
Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Moxifloxacin.
Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Moxifloxacin.
Gliclazide The therapeutic efficacy of Gliclazide can be increased when used in combination with Moxifloxacin.
Tolbutamide The therapeutic efficacy of Tolbutamide can be increased when used in combination with Moxifloxacin.
Pioglitazone The therapeutic efficacy of Pioglitazone can be increased when used in combination with Moxifloxacin.
Bromocriptine The therapeutic efficacy of Bromocriptine can be increased when used in combination with Moxifloxacin.
Gliquidone The therapeutic efficacy of Gliquidone can be increased when used in combination with Moxifloxacin.
Mitiglinide The therapeutic efficacy of Mitiglinide can be increased when used in combination with Moxifloxacin.
Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Moxifloxacin.
Sunitinib The therapeutic efficacy of Sunitinib can be increased when used in combination with Moxifloxacin.
Exenatide The therapeutic efficacy of Exenatide can be increased when used in combination with Moxifloxacin.
Mecasermin The therapeutic efficacy of Mecasermin can be increased when used in combination with Moxifloxacin.
Pramlintide The therapeutic efficacy of Pramlintide can be increased when used in combination with Moxifloxacin.
Glisoxepide The therapeutic efficacy of Glisoxepide can be increased when used in combination with Moxifloxacin.
Insulin aspart The therapeutic efficacy of Insulin aspart can be increased when used in combination with Moxifloxacin.
Insulin glulisine The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Moxifloxacin.
Glymidine The therapeutic efficacy of Glymidine can be increased when used in combination with Moxifloxacin.
AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Moxifloxacin.
Buformin The therapeutic efficacy of Buformin can be increased when used in combination with Moxifloxacin.
Vildagliptin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Moxifloxacin.
Voglibose The therapeutic efficacy of Voglibose can be increased when used in combination with Moxifloxacin.
NN344 The therapeutic efficacy of NN344 can be increased when used in combination with Moxifloxacin.
AMG-222 The therapeutic efficacy of AMG-222 can be increased when used in combination with Moxifloxacin.
Bisegliptin The therapeutic efficacy of Bisegliptin can be increased when used in combination with Moxifloxacin.
Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Moxifloxacin.
Dapagliflozin The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Moxifloxacin.
Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Moxifloxacin.
Liraglutide The therapeutic efficacy of Liraglutide can be increased when used in combination with Moxifloxacin.
Gosogliptin The therapeutic efficacy of Gosogliptin can be increased when used in combination with Moxifloxacin.
Linagliptin The therapeutic efficacy of Linagliptin can be increased when used in combination with Moxifloxacin.
Canagliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.
Glibornuride The therapeutic efficacy of Glibornuride can be increased when used in combination with Moxifloxacin.
Benfluorex The therapeutic efficacy of Benfluorex can be increased when used in combination with Moxifloxacin.
Empagliflozin The therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.
Albiglutide The therapeutic efficacy of Albiglutide can be increased when used in combination with Moxifloxacin.
Dulaglutide The therapeutic efficacy of Dulaglutide can be increased when used in combination with Moxifloxacin.
Lobeglitazone The therapeutic efficacy of Lobeglitazone can be increased when used in combination with Moxifloxacin.
Netoglitazone The therapeutic efficacy of Netoglitazone can be increased when used in combination with Moxifloxacin.
Rivoglitazone The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Moxifloxacin.
Ciglitazone The therapeutic efficacy of Ciglitazone can be increased when used in combination with Moxifloxacin.
Lixisenatide The therapeutic efficacy of Lixisenatide can be increased when used in combination with Moxifloxacin.
Insulin beef The therapeutic efficacy of Insulin beef can be increased when used in combination with Moxifloxacin.
Insulin degludec The therapeutic efficacy of Insulin degludec can be increased when used in combination with Moxifloxacin.
Insulin peglispro The therapeutic efficacy of Insulin peglispro can be increased when used in combination with Moxifloxacin.
Insulin tregopil The therapeutic efficacy of Insulin tregopil can be increased when used in combination with Moxifloxacin.
Ipragliflozin The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Moxifloxacin.
Dutogliptin The therapeutic efficacy of Dutogliptin can be increased when used in combination with Moxifloxacin.
Allicin The therapeutic efficacy of Allicin can be increased when used in combination with Moxifloxacin.
Tofogliflozin The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Moxifloxacin.
Ertugliflozin The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Moxifloxacin.
2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Moxifloxacin.
Teneligliptin The therapeutic efficacy of Teneligliptin can be increased when used in combination with Moxifloxacin.
Omarigliptin The therapeutic efficacy of Omarigliptin can be increased when used in combination with Moxifloxacin.
Carmegliptin The therapeutic efficacy of Carmegliptin can be increased when used in combination with Moxifloxacin.
Gemigliptin The therapeutic efficacy of Gemigliptin can be increased when used in combination with Moxifloxacin.

Target Protein

DNA gyrase subunit A gyrA
DNA gyrase subunit B gyrB
DNA gyrase subunit A gyrA
DNA topoisomerase 4 subunit A parC
DNA topoisomerase 2-alpha TOP2A
Serum paraoxonase/arylesterase 1 PON1

Referensi & Sumber

Synthesis reference: Manne Reddy, Sajja Eswaraiah, Vetukuri Venkata Naga Raju, Rapolu Kumar, Ningam Srinivasreddy, Vedantham Ravindra, "Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof." U.S. Patent US20050137227, issued June 23, 2005.
Artikel (PubMed)
  • PMID: 14614666
    Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub 2003 Nov 4.

Contoh Produk & Brand

Produk: 150 • International brands: 0
Produk
  • Act Moxifloxacin
    Solution • 0.5 % w/v • Ophthalmic • Canada • Approved
  • Ag-moxifloxacin
    Tablet • 400 mg • Oral • Canada • Generic • Approved
  • Ag-moxifloxacin
    Solution • 0.5 % w/v • Ophthalmic • Canada • Generic • Approved
  • Apo-moxifloxacin
    Solution • 0.5 % w/v • Ophthalmic • Canada • Generic • Approved
  • Apo-moxifloxacin
    Tablet • 400 mg • Oral • Canada • Generic • Approved
  • Apo-moxifloxacin Hydrochloride
    Tablet • 400 mg • Oral • Canada • Generic • Approved
  • Auro-moxifloxacin
    Tablet • 400 mg • Oral • Canada • Generic • Approved
  • Avelox
    Tablet, film coated • 400 mg/1 • Oral • US • Approved
Menampilkan 8 dari 150 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul